Last reviewed · How we verify
SODIUM PERTECHNETATE
At a glance
| Generic name | SODIUM PERTECHNETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (PHASE1)
- A Phase 2/3,PSMA-T4, Prostate Cancer (NA)
- Study of Venous Outflow From the Lower Limbs in Patients With Pelvic Varicosities
- Comparing Pertechnetate SPECT/CT and Intragastric Pressure During Nutrient Drink for Gastric Accommodation (NA)
- Simplification of Low Level Internal Dosimetry
- Preoperative Localization Strategies in Primary Hyperparathyroidism (NA)
- A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery (PHASE3)
- Thyroid Uptake Quantification on a New Generation of Gamma Camera
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODIUM PERTECHNETATE CI brief — competitive landscape report
- SODIUM PERTECHNETATE updates RSS · CI watch RSS